Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination

Leuk Lymphoma. 2010 Dec;51(12):2288-90. doi: 10.3109/10428194.2010.523127. Epub 2010 Oct 7.

Authors

Sylvain Pilorge, Sophie Park, François Dreyfus, Didier Bouscary, Jerome Tamburini

PMID: 20929331
DOI: 10.3109/10428194.2010.523127

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Blood Coagulation Disorders / chemically induced*
Blood Coagulation Disorders / mortality
Cyclophosphamide / administration & dosage
Humans
Male
Middle Aged
Rituximab
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives
Waldenstrom Macroglobulinemia / drug therapy*

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab
Cyclophosphamide
Vidarabine
fludarabine